Incretin Effect on the Immunological Phenotype

NCT01782261 on ClinicalTrials.gov · last registry update 2016-10-11

A small phase 2 — 15 participants, against a typical 110. The sponsor logged completion for February 2015. Primary outcome, as filed: Increase of regulatory FOXP3+ T cells. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Medical University of Graz
Sponsor type: Other
Enrollment: 15
Started: 2012-02
Primary completion: 2015-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Increase of regulatory FOXP3+ T cells

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.